No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Yifan Pharmaceutical Co., Ltd. (SZSE:002019) Surges 3.5%; Individual Investors Who Own 49% Shares Profited Along With Insiders
Yifan Pharmaceutical (002019.SZ): In the future, the company will continue to strive to explore key areas such as target discovery, compound screening, molecular design, pharmaceutical research, and clinical studies.
On February 24, Glonghui reported that Yifan Pharmaceutical (002019.SZ) has stated on the investor interaction platform that the company has begun to design some auxiliary tools and predictive functions in the field of macromolecule drug research and development. In the field of chemical drug research and development, applications have also been made in patent analysis, process route design, impurity evaluation, and pharmacological toxicology analysis. In the future, the company will continue to strive to attempt key areas such as target discovery, compound screening, molecular design, pharmaceutical research, and clinical research, dedicated to reducing research and development costs and improving research and development efficiency through cutting-edge technology.
Yifan Pharmaceutical (002019.SZ): The data organization and analysis for the Phase IB clinical trial of Duanjin detoxification capsules is expected to be completed by mid-year.
Gelonghui reported on February 17 that Yifan Pharmaceutical (002019.SZ) stated on the investor interaction platform that the clinical trial phase IB for the product Duanjin Detoxification Capsules is expected to complete data sorting and analysis by mid-year.
Yifan Pharmaceutical (002019.SZ): Currently, Yili Shu is exported to the USA using the EXW method, meaning that the buyer bears the customs duties.
On February 14, Gelonghui reported that Yifan Pharmaceutical (002019.SZ) stated on the investor interaction platform that currently, Yilishu is exported to the USA using EXW (Ex Works) delivery terms, meaning the buyer is responsible for the customs duties. If the final customs duties have a significant impact, negotiations will be conducted with the partners to find a joint solution.
Yifan Pharmaceutical (002019.SZ): subsidiary recognized as a high-tech enterprise.
On February 13, Gelonghui reported that Yifan Pharmaceutical (002019.SZ) announced that its holding subsidiary Peking Jisheng Kangtai International Pharmaceutical Technology Co., Ltd. (referred to as "Peking Jisheng Kangtai") and wholly-owned subsidiary Yifan Pharmaceutical Research Institute (Beijing) Co., Ltd. (referred to as "Yifan Research Institute") received the "High-tech Enterprise Certificate" jointly issued by the Beijing Municipal Science and Technology Commission, the Beijing Municipal Finance Bureau, and the State Administration of Taxation Beijing Taxation Bureau on February 12, 2025.
Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Share Price Not Quite Adding Up